• Broad coverage extended to Japan and related regions

SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Ovarian Cancer Vaccines."

Anixa Chairman and CEO Dr. Amit Kumar commented, "This new Japanese patent extends the expanded claims for this novel ovarian cancer vaccine technology to another geographic region, joining the European and U.S. patents awarded last year. As the exclusive worldwide licensee of the technology, we highly value the broad protection this patent provides as our research and development continues. If our vaccine is approved, one of the most aggressive gynecological cancers could be prevented from ever developing in women globally."

The Ovarian Cancer Vaccines patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic. The researchers demonstrated in pre-clinical studies that vaccination against the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) significantly inhibits tumor growth and enhances overall survival. The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer.

Anixa is the exclusive worldwide licensee for the vaccine technology from Cleveland Clinic, a nonprofit, multispecialty academic medical center. Preclinical work on the vaccine is supported by the National Cancer Institute's PREVENT Program, a peer-reviewed program designed to support development of the best ideas in cancer prevention.

About Anixa Bioscience's Ovarian Cancer Vaccine

Anixa's ovarian cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED) which regulates growth and development of egg-containing follicles in the ovaries and is expressed throughout much of a woman's life, with expression naturally and markedly declining during menopause, but which is present in the majority of endothelian ovarian carcinomas. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging ovarian tumors that express AMHR2-ED. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing. This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Dr. Tuohy was inventor of the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences. He was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in Anixa.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
408-708-9808